Ursodeoxycholyl lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD

Background Hepatic fat accumulation with disturbed lipid homoeostasis is a hallmark of nonalcoholic fatty liver disease (NAFLD). The bile acid phospholipid conjugate Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) is a novel anti-inflammatory agent with hepatoprotective effects in murine hig...

Full description

Saved in:
Bibliographic Details
Main Authors: Pathil-Warth, Anita (Author) , Liebisch, Gerhard (Author) , Okun, Jürgen G. (Author) , Chamulitrat, Walee (Author) , Schmitz, Gerd (Author) , Stremmel, Wolfgang (Author)
Format: Article (Journal)
Language:English
Published: 24 June 2015
In: European journal of clinical investigation
Year: 2015, Volume: 45, Issue: 9, Pages: 925-931
ISSN:1365-2362
DOI:10.1111/eci.12486
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/eci.12486
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.12486
Get full text
Author Notes:Anita Pathil, Gerhard Liebisch, Jürgen G. Okun, Walee Chamulitrat, Gerd Schmitz and Wolfgang Stremmel

MARC

LEADER 00000caa a2200000 c 4500
001 1703013441
003 DE-627
005 20230427154001.0
007 cr uuu---uuuuu
008 200701s2015 xx |||||o 00| ||eng c
024 7 |a 10.1111/eci.12486  |2 doi 
035 |a (DE-627)1703013441 
035 |a (DE-599)KXP1703013441 
035 |a (OCoLC)1341342139 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Pathil-Warth, Anita  |d 1981-  |e VerfasserIn  |0 (DE-588)132644304  |0 (DE-627)524715890  |0 (DE-576)260118915  |4 aut 
245 1 0 |a Ursodeoxycholyl lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD  |c Anita Pathil, Gerhard Liebisch, Jürgen G. Okun, Walee Chamulitrat, Gerd Schmitz and Wolfgang Stremmel 
264 1 |c 24 June 2015 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 01.07.2020 
520 |a Background Hepatic fat accumulation with disturbed lipid homoeostasis is a hallmark of nonalcoholic fatty liver disease (NAFLD). The bile acid phospholipid conjugate Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) is a novel anti-inflammatory agent with hepatoprotective effects in murine high-fat-diet (HFD)-induced NAFLD. The aim of this work was to study changes in the hepatic lipidome due to UDCA-LPE. Materials and methods High fat diet mouse model, mass spectometry, RT-PCR. Results Hepatic lipid extracts of HFD mice were analysed by mass spectrometry. The results determined higher levels of total, saturated, mono- and diunsaturated fatty acids (FA) in HFD mice, which were decreased by UDCA-LPE predominantly by the reducing the most abundant FA species palmitic acid and oleic acid. Unlike other FA species, levels of long-chain polyunsaturated fatty acids (LCPUFA), which are composed of arachidonic acid (ARA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), were increased in HFD mice upon UDCA-LPE treatment, mainly due to elevated hepatic ARA pools. Analysis of hepatic phospholipids species showed a decrease in total phosphatidylcholine (PC), especially monounsaturated PC (PUFA-PC) levels in HFD mice. Loss of total PC was reversed due to UDCA-LPE by increasing hepatic PUFA-PC pools. Gene expression analysis showed that UDCA-LPE upregulated PPARα, a key transcriptional regulator of fatty acid oxidation, as well as downstream target genes CPT1α and AOX, which are crucially involved in mitochondrial and peroxisomal fatty acid oxidation. Conclusion UDCA-LPE modulates defective fatty acid metabolism during experimental NAFLD thereby restoring altered lipid profiles in addition to its pronounced anti-inflammatory effects. Thus, UDCA-LPE may be a promising drug candidate for the management of NAFLD. 
650 4 |a Fatty acid composition 
650 4 |a non-alcoholic fatty liver disease 
650 4 |a UDCA-LPE 
700 1 |a Liebisch, Gerhard  |e VerfasserIn  |4 aut 
700 1 |a Okun, Jürgen G.  |d 1968-  |e VerfasserIn  |0 (DE-588)121578232  |0 (DE-627)705551415  |0 (DE-576)292781296  |4 aut 
700 1 |a Chamulitrat, Walee  |d 1959-  |e VerfasserIn  |0 (DE-588)1037336828  |0 (DE-627)755493915  |0 (DE-576)39134479X  |4 aut 
700 1 |a Schmitz, Gerd  |e VerfasserIn  |4 aut 
700 1 |a Stremmel, Wolfgang  |d 1952-  |e VerfasserIn  |0 (DE-588)142773638  |0 (DE-627)640118747  |0 (DE-576)33331560X  |4 aut 
773 0 8 |i Enthalten in  |t European journal of clinical investigation  |d Oxford [u.a.] : Wiley-Blackwell, 1970  |g 45(2015), 9, Seite 925-931  |h Online-Ressource  |w (DE-627)320441423  |w (DE-600)2004971-7  |w (DE-576)091142695  |x 1365-2362  |7 nnas  |a Ursodeoxycholyl lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD 
773 1 8 |g volume:45  |g year:2015  |g number:9  |g pages:925-931  |g extent:7  |a Ursodeoxycholyl lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD 
856 4 0 |u https://doi.org/10.1111/eci.12486  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.12486  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200701 
993 |a Article 
994 |a 2015 
998 |g 142773638  |a Stremmel, Wolfgang  |m 142773638:Stremmel, Wolfgang  |d 910000  |d 910100  |e 910000PS142773638  |e 910100PS142773638  |k 0/910000/  |k 1/910000/910100/  |p 6  |y j 
998 |g 1037336828  |a Chamulitrat, Walee  |m 1037336828:Chamulitrat, Walee  |d 910000  |d 910100  |e 910000PC1037336828  |e 910100PC1037336828  |k 0/910000/  |k 1/910000/910100/  |p 4 
998 |g 121578232  |a Okun, Jürgen G.  |m 121578232:Okun, Jürgen G.  |d 910000  |d 910500  |e 910000PO121578232  |e 910500PO121578232  |k 0/910000/  |k 1/910000/910500/  |p 3 
998 |g 132644304  |a Pathil-Warth, Anita  |m 132644304:Pathil-Warth, Anita  |d 910000  |d 910100  |e 910000PP132644304  |e 910100PP132644304  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1703013441  |e 3692619200 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"given":"Anita","role":"aut","display":"Pathil-Warth, Anita","family":"Pathil-Warth"},{"role":"aut","given":"Gerhard","family":"Liebisch","display":"Liebisch, Gerhard"},{"given":"Jürgen G.","role":"aut","display":"Okun, Jürgen G.","family":"Okun"},{"family":"Chamulitrat","display":"Chamulitrat, Walee","role":"aut","given":"Walee"},{"display":"Schmitz, Gerd","family":"Schmitz","given":"Gerd","role":"aut"},{"family":"Stremmel","display":"Stremmel, Wolfgang","role":"aut","given":"Wolfgang"}],"physDesc":[{"extent":"7 S."}],"relHost":[{"disp":"Ursodeoxycholyl lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLDEuropean journal of clinical investigation","origin":[{"publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedDisp":"1970-","dateIssuedKey":"1970","publisherPlace":"Oxford [u.a.] ; Oxford [u.a.] ; Oxford [u.a.]"}],"part":{"issue":"9","pages":"925-931","volume":"45","text":"45(2015), 9, Seite 925-931","year":"2015","extent":"7"},"recId":"320441423","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"the journal of the European Society for Clinical Investigation","title":"European journal of clinical investigation","title_sort":"European journal of clinical investigation"}],"id":{"eki":["320441423"],"doi":["10.1111/(ISSN)1365-2362"],"issn":["1365-2362"],"zdb":["2004971-7"]},"pubHistory":["1.1970/71 -"]}],"title":[{"title_sort":"Ursodeoxycholyl lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD","title":"Ursodeoxycholyl lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1703013441"],"doi":["10.1111/eci.12486"]},"origin":[{"dateIssuedDisp":"24 June 2015","dateIssuedKey":"2015"}],"recId":"1703013441","note":["Gesehen am 01.07.2020"],"language":["eng"],"name":{"displayForm":["Anita Pathil, Gerhard Liebisch, Jürgen G. Okun, Walee Chamulitrat, Gerd Schmitz and Wolfgang Stremmel"]}} 
SRT |a PATHILWARTURSODEOXYC2420